Based in Waltham, MA, Affinia Therapeutics is an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene therapies for rare and prevalent devastating conditions, including next-generation gene therapies for patients with neurologic and neuro-oncologic diseases. AlloVir Chief Executive Officer, Diana Brainard, MD, and retired EY Partner, Carole Faig, were appointed…